{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:36:07Z","timestamp":1793126167738,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor\/glucagon\u2010like peptide\u20101 receptor (GLP\u20101R) dual agonist with the potential to induce greater weight reductions than GLP\u20101R mono\u2010agonists. We report the design and baseline participant characteristics of the SYNCHRONIZE\u2010JP trial evaluating survodutide in Japanese adults with obesity disease (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      : NCT06176365).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      SYNCHRONIZE\u2010JP is a 76\u2010week, randomised, double\u2010blind, parallel\u2010group, multi\u2010centre, phase 3 clinical trial. Eligible participants were aged \u2265\u200918\u2009years, with BMI \u2265\u200935\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with \u2265\u20091 obesity complication or BMI \u2265\u200927\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with \u2265\u20092 obesity complications, \u2265\u20091 self\u2010reported unsuccessful dietary effort to lose body weight and \u2265\u20091 obesity complication required to be type 2 diabetes (T2D; capped at 30% enrolment), hypertension or dyslipidaemia. Participants were randomised 1:1:1 to receive once\u2010weekly survodutide 3.6 or 6.0\u2009mg, or placebo, accompanied by a reduced\u2010calorie diet and increased physical activity. The primary endpoints are percentage change in body weight and achievement of body weight reduction \u2265\u20095% from baseline to Week 76. A subset of participants will be assessed for additional endpoints of liver fat content and body composition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 274 enrolled participants, 24.1% had T2D. The mean age was 53.1\u2009years; 47.8% were female, and mean BMI was 33.2\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The most frequent complications were dyslipidaemia (81.4%), hypertension (72.6%), hyperuricaemia (30.3%) and metabolic dysfunction\u2010associated steatotic liver disease (26.6%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of SYNCHRONIZE\u2010JP will provide Japan\u2010specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70862","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:10:35Z","timestamp":1780272635000},"page":"6595-6606","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3\n                    <scp>SYNCHRONIZE<\/scp>\n                    \u2010\n                    <scp>JP<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-4813","authenticated-orcid":false,"given":"Koutaro","family":"Yokote","sequence":"first","affiliation":[{"name":"Chiba University  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-6404","authenticated-orcid":false,"given":"Toshimasa","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Metabolic Diseases Graduate School of Medicine, The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-215X","authenticated-orcid":false,"given":"Yasushi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Fukuwa Clinic  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3777-3510","authenticated-orcid":false,"given":"Yoji","family":"Takatsuka","sequence":"additional","affiliation":[{"name":"Motomachi Takatsuka Internal Medicine Clinic  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0220-3829","authenticated-orcid":false,"given":"Marie","family":"Kato","sequence":"additional","affiliation":[{"name":"Nippon Boehringer Ingelheim Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2328-1726","authenticated-orcid":false,"given":"Shijia","family":"Yan","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim (China) Investment Co. Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-2395","authenticated-orcid":false,"given":"Takayoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Nippon Boehringer Ingelheim Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6826-0822","authenticated-orcid":false,"given":"Luiza","family":"Borowska","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-0746","authenticated-orcid":false,"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"},{"name":"First Department of Medicine Faculty of Medicine Mannheim, University of Heidelberg  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-4366","authenticated-orcid":false,"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Section of Metabolic Diseases, Division of Translational Science Kobe University Graduate School of Medicine  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SYNCHRONIZE\u2010JP Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organisation \u201cObesity and Overweight \u201d2025 accessed May 15 2025 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155217"},{"key":"e_1_2_11_4_1","unstructured":"Global Obesity Observatory \u201c% Adults Living With Overweight or Obesity 1973\u20132023 \u201d2025 accessed May 16 2025 https:\/\/data.worldobesity.org\/country\/japan\u2010105\/#data_trends."},{"key":"e_1_2_11_5_1","unstructured":"World Obesity Federation \u201cWorld Obesity Atlas \u201d2023 accessed May 16 2025 https:\/\/s3\u2010eu\u2010west\u20101.amazonaws.com\/wof\u2010files\/World_Obesity_Atlas_2023_Report.pdf."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02750-2"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2024.123991"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.15420\/japsc.2023.68"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0416"},{"key":"e_1_2_11_10_1","volume-title":"Metabolic Syndrome","author":"Park Y.\u2010M. M.","year":"2023"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0593"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69703-1"},{"key":"e_1_2_11_13_1","unstructured":"World Health Organisation Western Pacific Region \u201cThe Asia\u2010Pacific Perspective: Redefining Obesity and Its Treatment \u201d2000 accessed May 16 2025 https:\/\/iris.who.int\/handle\/10665\/206936."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31150"},{"key":"e_1_2_11_15_1","volume-title":"Japan Society for the Study of Obesity (2022) Guidelines for the Management of Obesity Disease 2022","author":"Japan Society for the Study of Obesity","year":"2022"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"issue":"15","key":"e_1_2_11_17_1","first-page":"S288","article-title":"A Review of Current Guidelines for the Treatment of Obesity","volume":"28","author":"Cornier M. A.","year":"2022","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442721"},{"issue":"2","key":"e_1_2_11_21_1","first-page":"453","article-title":"Associations Between Health Interest Scale Dimensions and Obesity Risk: A Cross\u2010Sectional Study Among Japanese Employees","volume":"8","author":"Iwase Y.","year":"2025","journal-title":"JMA Journal"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02941-7"},{"key":"e_1_2_11_23_1","unstructured":"Zepbound \u201c\u2018Zepbound\u2019 a Long\u2010Acting GIP\/GLP\u20101 Receptor Agonist Approved for the Chronic Disease of \u2018Obesity Disease\u2019 With Multiple Factors \u201d2024 accessed June 24 2025 https:\/\/www.tanabe\u2010pharma.com\/en\/news\/storage\/20241227103031\/pdf\/e_MTPC241227.pdf."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15638"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00356-X"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14948"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2016"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735019"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06053-9"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24184"},{"key":"e_1_2_11_33_1","unstructured":"ClinicalTrials.gov. NCT06066515 \u201cA Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE\u20101) \u201daccessed May 12 2025 https:\/\/clinicaltrials.gov\/study\/NCT06066515."},{"key":"e_1_2_11_34_1","unstructured":"ClinicalTrials.gov. NCT06066528 \u201cA Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE\u20102) \u201daccessed May 12 2025 https:\/\/clinicaltrials.gov\/study\/NCT06066528."},{"key":"e_1_2_11_35_1","unstructured":"ClinicalTrials.gov. NCT06176365 \u201cA Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease (SYNCHRONIZE\u2010JP) \u201daccessed May 12 2025 https:\/\/clinicaltrials.gov\/study\/NCT06176365."},{"key":"e_1_2_11_36_1","unstructured":"ClinicalTrials.gov. NCT06214741 \u201cA Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight \u201daccessed May 15 2025 https:\/\/www.clinicaltrials.gov\/study\/NCT06214741."},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.09.004"},{"key":"e_1_2_11_38_1","unstructured":"ClinicalTrials.gov. NCT06077864 \u201cA Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE\u2010CVOT) \u201daccessed May 12 2025 https:\/\/clinicaltrials.gov\/study\/NCT06077864."},{"key":"e_1_2_11_39_1","unstructured":"ClinicalTrials.gov. NCT06309992 \u201cA Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non\u2010Alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight \u201daccessed October 31 2025 https:\/\/clinicaltrials.gov\/study\/NCT06309992."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24299"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.70021"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15268-3"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789X.2002.00065.x"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14764"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16306"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1103"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09796-3"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2025.05.001"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00008-0"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00377-2"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.70178"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70862","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70862","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:17:35Z","timestamp":1793125055000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/dom.70862"],"URL":"https:\/\/doi.org\/10.1111\/dom.70862","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"2026-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}